ReviewOncogenesis2016
Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.
Review in Oncogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Exercise-induced modulation of IGF-1 in healthy, obese, and cancer populations: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Protein intake and cancer: an umbrella review of systematic reviews for the evidence-based guideline of the German Nutrition Society.European journal of nutrition · 2024Pooled it
- Pooled it
- Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.British journal of cancer · 2022Trial
- Causal relationship between metabolic syndrome and gastric cancer: insights from comprehensive analysis and biomarker identification.Translational cancer research · 2026Article
- Metabolic Modulation for Cancer Pain Relief: A Retrospective Pilot Study.Journal of pain research · 2026Article
- Nutritional approaches in combating therapeutic resistance and enhancing treatment efficacy in cancer: the impact of ketogenic diets.Nutrition & metabolism · 2025Review
- The Role of Diet and Nutrition in Cancer Development and Management: From Molecular Mechanisms to Personalized Interventions.Foods (Basel, Switzerland) · 2025Review
- Proteomic analysis across aged tissues reveals distinct signatures and the crucial involvement of midgut barrier function in the regulation of aging.Aging cell · 2025Article
- The dual role of gut microbiota in pancreatic cancer: new insights into onset and treatment.Therapeutic advances in medical oncology · 2025Review
- Nutrition, GH/IGF-1 signaling, and cancer.Endocrine-related cancer · 2024Review
- Metabolomic Profiling of Tumor Tissues Unveils Metabolic Shifts in Non-Small Cell Lung Cancer Patients with Concurrent Diabetes Mellitus.Journal of proteome research · 2024Article
- Healthy dietary patterns and risk of prostate cancer in men at high genetic risk.International journal of cancer · 2024Article
- An unexpected role for the ketogenic diet in triggering tumor metastasis by modulating BACH1-mediated transcription.Science advances · 2024Article
- Sex-specific effects of dietary restriction on physiological variables in Japanese quails.Ecology and evolution · 2024Article
- High-protein diet scores, macronutrient substitution, and breast cancer risk: insights from substitution analysis.BMC women's health · 2024Article
- Nutrient restriction-activated Fra-2 promotes tumor progression via IGF1R in miR-15a downmodulated pancreatic ductal adenocarcinoma.Signal transduction and targeted therapy · 2024Article
- Review
- Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy.Cancer metastasis reviews · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As more and more links between cancer and metabolism are discovered, new approaches to treat cancer using these mechanisms are considered. Dietary restriction of either calories or macronutrients has shown great potential in animal studies to both reduce the incidence and growth of cancer, and to act synergistically with other treatment strategies. These studies have also shown that dietary restriction simultaneously targets many of the molecular pathways that are targeted individually by anticancer drugs. The insulin/insulin-like growth factor-1 (IGF-1) system has thereby emerged as a key regulator of cancer growth pathways. Although lowering of insulin levels with diet or drugs such as metformin and diazoxide seems generally beneficial, some practitioners also utilize strategic elevations of insulin levels in combination with chemotherapeutic drugs. This indicates a broad spectrum of possibilities for modulating the insulin/IGF-1 system in cancer treatment. With a specific focus on dietary restriction, insulin administration and the insulin-lowering drug diazoxide, such modifications of the insulin/IGF-1 system are the topic of this review. Although preclinical data are promising, we point out that insulin regulation and the metabolic response to a certain diet often differ between mice and humans. Thus, the need for collecting more human data has to be emphasized.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.